Advanced nanomedicines for the treatment and diagnosis of myocardial infarction and heart failure

Current Drug Targets

Volumn 16, Issue 14, 2015, Pages 1682-1697

  Ferreira, Mónica P A ^a   Balasubramanian, Vimalkumar ^a   Hirvonen, Jouni ^a   Ruskoaho, Heikki ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiac biomarkers; Cardiovascular diseases; Imaging; Myocardial infarction; Nanomedicine; Nanoparticles

Indexed keywords

ADENOSINE; ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; BIOLOGICAL MARKER; CARBON NANOFIBER; CARBON NANOTUBE; COLLAGEN TYPE 1; CONTRAST MEDIUM; DENDRIMER; FERUMOXYTOL; FLUORINE 18; FLUOROCARBON; GADOLINIUM PENTETATE; GADOTERIC ACID; GOLD NANOPARTICLE; GOLD NANOROD; HYALURONIC ACID; LIPOSOME; MACROGOL; MOLECULAR SCAFFOLD; MYOSIN; NANOFIBER; NANOPARTICLE; PERFLUOROPENTANE; SILICA NANOPARTICLE; SILICON; STROMAL CELL DERIVED FACTOR 1; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; DRUG CARRIER;

CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; EXTRACELLULAR MATRIX; GENE TARGETING; HEART ATRIUM REMODELING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYDROGEL; IMAGING; MESENCHYMAL STEM CELL; MOLECULAR IMAGING; NANOEMULSION; NANOMEDICINE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CARDIOMYOPATHIES; PROCEDURES; PROGNOSIS; TRENDS;

CARDIOMYOPATHIES; CELL- AND TISSUE-BASED THERAPY; DRUG CARRIERS; HEART FAILURE; HUMANS; NANOMEDICINE; PROGNOSIS;

EID: 84951871771     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115999141030143923     Document Type: Review

References (124)

1. World Health Organization (WHO): Cardiovascular diseases (CVDs). Avaiable at http://www.who.int/mediacentre/factsheets/fs317/en/ accessed May 30, 2014].
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation 2013; 1(127): e6-e245.
3. CardioPulse articles: European cardiovascular disease statistics 4th Edition 2012: EuroHeart II Eur Heart J 2013; 39(34): 3007-13.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 39(34): 3028-34.
5. Thygesen K, Alpert JS, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2007; 22(50): 2173-95.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 16(60): 1581-98.
7. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGFencapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 2009; 10(23): 3361-7.
8. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 13(358): 1370-80.
9. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013; 1(123): 37-45.
10. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011; 9792(378): 704-12.
11. Santos CX, Anilkumar N, Zhang M, Brewer AC, Shah AM. Redox signaling in cardiac myocytes. Free Radic Biol Med 2011; 7(50): 777-93.
12. Krum H, Teerlink JR. Medical therapy for chronic heart failure. Lancet 2011; 9792(378): 713-21.
13. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 20(348): 2007-18.
14. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 3(19): 311-30.
15. Eniola-Adefeso O, Heslinga MJ, Porter TM. Design of nanovectors for therapy and imaging of cardiovascular diseases. Methodist Debakey Cardiovasc J 2012; 1(8): 13-7.
16. Paulis LE, Geelen T, Kuhlmann MT, et al. Distribution of lipidbased nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J Control Release 2012; 2(162): 276-85.
17. Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009; 6(8): 526-33.
18. Chang MY, Yang YJ, Chang CH, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release 2013; 2(170): 287-94.
19. Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003; 2(101): 560-7.
20. Lu ZX, Mao LL, Lian F, et al. Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: Nanoparticle-based delivery versus direct myocardial injection. BMC Cardiovasc Disord 2014; 1(14): 53.
21. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008; 3(68): 513-25.
22. Binsalamah ZM, Paul A, Khan AA, Prakash S, Shum-Tim D. Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int J Nanomedicine 20116: 2667-78.
23. Somasuntharam I, Boopathy AV, Khan RS, et al. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 2013; 31(34): 7790-8.
24. Tranter M, Liu Y, He S, et al. In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo. Mol Ther 2012; 3(20): 601-8.
25. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001; 2(38): 307-14.
26. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 1999; 12(100): 1330-7.
27. Vinodhini A, Govindaraju K, Singaravelu G, Mohamed Sadiq A, Kumar VG. Cardioprotective potential of biobased gold nanoparticles. Colloids Surf B Biointerfaces 2014117: 480-6.
28. Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 2000; 2-3(148): 187-97.
29. Ye X, Krohn RL, Liu W, et al. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 1999; 1-2(196): 99-108.
30. Sisco PN, Wilson CG, Mironova E, et al. The effect of gold nanorods on cell-mediated collagen remodeling. Nano Lett 2008; 10(8): 3409-12.
31. Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 2011; 3(8): 188-96.
32. Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine 20105: 231-7.
33. Laubach VE, French BA, Okusa MD. Targeting of adenosine receptors in ischemia-reperfusion injury. Expert Opin Ther Targets 2011; 1(15): 103-18.
34. Galagudza M, Korolev D, Postnov V, et al. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine 20127: 1671-8.
35. Tölli MA, Ferreira MPA, Kinnunen SM, et al. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. Biomaterials 2014; 29(35): 8394-405.
36. Vlasova MA, Tarasova OS, Riikonen J, et al. Injected nanoparticles: The combination of experimental systems to assess cardiovascular adverse effects. Eur J Pharm Biopharm 2014; 1(87): 64-72.
37. Lee CM, Lee HC, Lee KY. O-palmitoylcurdlan sulfate (OPCurS)- coated liposomes for oral drug delivery. J Biosci Bioeng 2005; 3(100): 255-9.
38. Levchenko TS, Hartner WC, Torchilin VP. Liposomes in diagnosis and treatment of cardiovascular disorders. Methodist Debakey Cardiovasc J 2012; 1(8): 36-41.
39. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009; 8(53): 709-17.
40. Herve K, Douziech-Eyrolles L, Munnier E, et al. The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications. Nanotechnology 2008; 46(19): 465608.
41. Lankveld DP, Rayavarapu RG, Krystek P, et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine (Lond) 2011; 2(6): 339-49.
42. Khaw BA, Torchilin VP, Vural I, Narula J. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1995; 11(1): 1195-8.
43. Liang W, Levchenko T, Khaw BA, Torchilin V. ATP-containing immunoliposomes specific for cardiac myosin. Curr Drug Deliv 2004; 1(1): 1-7.
44. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target 2006; 5(14): 273-80.
45. Khaw BA, DaSilva J, Hartner WC. Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability. J Control Release 2007; 1-2(120): 35-40.
46. Rysä J, Tenhunen O, Serpi R, et al. GATA-4 is an angiogenic survival factor of the infarcted heart. Circ Heart Fail 2010; 3(3): 440-50.
47. Moilanen AM, Rysa J, Mustonen E, et al. Intramyocardial BNP gene delivery improves cardiac function through distinct contextdependent mechanisms. Circ Heart Fail 2011; 4(4): 483-95.
48. Ko YT, Hartner WC, Kale A, Torchilin VP. Gene delivery into ischemic myocardium by double-targeted lipoplexes with antimyosin antibody and TAT peptide. Gene Ther 2009; 1(16): 52-9.
49. Scott RC, Wang B, Nallamothu R, et al. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 2007; 4(96): 795-802.
50. Molavi B, Chen J, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 2006; 2(291): H687-93.
51. Dvir T, Bauer M, Schroeder A, et al. Nanoparticles targeting the infarcted heart. Nano Lett 2011; 10(11): 4411-4.
52. Geelen T, Paulis LE, Coolen BF, Nicolay K, Strijkers GJ. Passive targeting of lipid-based nanoparticles to mouse cardiac ischemiareperfusion injury. Contrast Media Mol Imaging 2013; 2(8): 117-26.
53. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 29(33): 7138-50.
54. Liu J, Gu C, Cabigas EB, et al. Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials 2013; 14(34): 3729-36.
55. Correas JM, Meuter AR, Singlas E, et al. Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography. Ultrasound Med Biol 2001; 4(27): 565-70.
56. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br Med Bull 1999; 1(55): 277-98.
57. Swyer T, Strom J, Larson D. Nanoparticle oxygen delivery to the ischemic heart. Perfusion 2014.
58. Edelberg JM, Lee SH, Kaur M, et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002; 5(105): 608-13.
59. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 10(115): 2691-4.
60. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2006; 1(116): 237-48.
61. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 7(114): 637-44.
62. Bastings MMC, Koudstaal S, Kieltyka RE, et al. A fast pHswitchable and self-healing supramolecular hydrogel carrier for guided, local catheter injection in the infarcted myocardium. Adv Healthcare Mater 2014; 1(3): 70-8.
63. Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. Theoretical impact of the injection of material into the myocardium: A finite element model simulation. Circulation 2006; 24(114): 2627-35.
64. Plotkin M, Vaibavi SR, Rufaihah AJ, et al. The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack. Biomaterials 2014; 5(35): 1429-38.
65. Dai S, Yuan F, Mu J, et al. Chronic AMD3100 antagonism of SDF- 1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol 2010; 4(49): 587-97.
66. Lin C-C, Metters A. Enhanced protein delivery from photopolymerized hydrogels using a pseudospecific metal chelating ligand. Pharm Res 2006; 3(23): 614-22.
67. Schesny MK, Monaghan M, Bindermann AH, et al. Preserved bioactivity and tunable release of a SDF1-GPVI bi-specific protein using photo-crosslinked PEGda hydrogels. Biomaterials 2014.
68. Yoon SJ, Fang YH, Lim CH, et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. J Biomed Mater Res B Appl Biomater 2009; 1(91): 163-71.
69. Yoon SJ, Hong S, Fang YH, et al. Differential regeneration of myocardial infarction depending on the progression of disease and the composition of biomimetic hydrogel. J Biosci Bioeng 2014.
70. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004; 8(103): 2981-9.
71. Purcell BP, Elser JA, Mu A, Margulies KB, Burdick JA. Synergistic effects of SDF-1α chemokine and hyaluronic acid release from degradable hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials 2012; 31(33): 7849-57.
72. Song M, Jang H, Lee J, et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP. Biomaterials 2014; 8(35): 2436-45.
73. MacArthur JW, Jr., Purcell BP, Shudo Y, et al. Sustained release of engineered stromal cell-derived factor 1-alpha from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction. Circulation 2013; 11 Suppl 1(128): S79-86.
74. Boopathy A, Davis M. In Drug delivery system, Kewal K. Jain, ed.; Springer New York, 2014; Vol. 1141, pp. 159-64.
75. Rufaihah AJ, Vaibavi SR, Plotkin M, et al. Enhanced infarct stabilization and neovascularization mediated by VEGF-loaded PEGylated fibrinogen hydrogel in a rodent myocardial infarction model. Biomaterials 2013; 33(34): 8195-202.
76. Projahn D, Simsekyilmaz S, Singh S, et al. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction. J Cell Mol Med 2014; 5(18): 790-800.
77. Collins JM, Russell B. Stem cell therapy for cardiac repair. J Cardiovasc Nurs 2009; 2(24): 93-7.
78. Oh B, Lee CH. Nanofiber for cardiovascular tissue engineering. Expert Opin Drug Deliv 2013; 11(10): 1565-82.
79. Venugopal JR, Prabhakaran MP, Mukherjee S, et al. Biomaterial strategies for alleviation of myocardial infarction. J R Soc Interface 2012; 66(9): 1-19.
80. Giraud MN, Guex AG, Tevaearai HT. Cell therapies for heart function recovery: focus on myocardial tissue engineering and nanotechnologies. Cardiol Res Pract 20122012: 971614.
81. Ravichandran R, Venugopal JR, Sundarrajan S, et al. Expression of cardiac proteins in neonatal cardiomyocytes on PGS/fibrinogen core/shell substrate for Cardiac tissue engineering. Int J Cardiol 2013; 4(167): 1461-8.
82. Ravichandran R, Seitz V, Reddy Venugopal J, et al. Mimicking native extracellular matrix with phytic acid-crosslinked protein nanofibers for cardiac tissue engineering. Macromol Biosci 2013; 3(13): 366-75.
83. Venugopal J, Rajeswari R, Shayanti M, et al. Xylan polysaccharides fabricated into nanofibrous substrate for myocardial infarction. Mater Sci Eng C Mater Biol Appl 2013; 3(33): 1325-31.
84. Kai D, Wang QL, Wang HJ, et al. Stem cell-loaded nanofibrous patch promotes the regeneration of infarcted myocardium with functional improvement in rat model. Acta Biomater 2014; 6(10): 2727-38.
85. Zhang Y, Thorn S, DaSilva JN, et al. Collagen-based matrices improve the delivery of transplanted circulating progenitor cells: development and demonstration by ex vivo radionuclide cell labeling and in vivo tracking with positron-emission tomography. Circ Cardiovasc Imaging 2008; 3(1): 197-204.
86. Suuronen EJ, Veinot JP, Wong S, et al. Tissue-engineered injectable collagen-based matrices for improved cell delivery and vascularization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood. Circulation 2006; 1 Suppl(114): I138-44.
87. Gishto A, Farrell K, Kothapalli CR. Tuning composition and architecture of biomimetic scaffolds for enhanced matrix synthesis by murine cardiomyocytes. J Biomed Mater Res A 2014.
88. Ahmadi A, McNeill B, Vulesevic B, et al. The role of integrin alpha2 in cell and matrix therapy that improves perfusion, viability and function of infarcted myocardium. Biomaterials 2014; 17(35): 4749-58.
89. Wang H, Shi J, Wang Y, et al. Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction. Biomaterials 2014; 13(35): 3986-98.
90. Li J, Shu Y, Hao T, et al. A chitosan-glutathione based injectable hydrogel for suppression of oxidative stress damage in cardiomyocytes. Biomaterials 2013; 36(34): 9071-81.
91. Cui H, Liu Y, Cheng Y, et al. In vitro study of electroactive tetraaniline-containing thermosensitive hydrogels for cardiac tissue engineering. Biomacromolecules 2014; 4(15): 1115-23.
92. Balasubramanian P, Prabhakaran MP, Kai D, Ramakrishna S. Human cardiomyocyte interaction with electrospun fibrinogen/gelatin nanofibers for myocardial regeneration. J Biomater Sci Polym Ed 2013; 14(24): 1660-75.
93. Altintas Z, Fakanya WM, Tothill IE. Cardiovascular disease detection using bio-sensing techniques. Talanta 2014; 0(128): 177-86.
94. Grainger, DJ. Metabolic profiling in heart disease. Heart Metab 2006; 32:22-5.
95. Jaffer FA, Sosnovik DE, Nahrendorf M, Weissleder R. Molecular imaging of myocardial infarction. J Mol Cell Cardiol 2006; 6(41): 921-33.
96. Zhu D, Liu F, Ma L, Liu D, Wang Z. Nanoparticle-based systems for t1-weighted magnetic resonance imaging contrast agents. Int J Mol Sci 2013; 5(14): 10591-607.
97. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011; 10(44): 979-89.
98. Chen W, Cormode DP, Fayad ZA, Mulder WJ. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010.
99. Xu W, Kattel K, Park JY, et al. Paramagnetic nanoparticle T1 and T2 MRI contrast agents. Phys Chem Chem Phys 2012; 37(14): 12687-700.
100. Sosnovik DE, Nahrendorf M, Weissleder, R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007; 15(115): 2076-86.
101. Meincke M, Schlorf T, Kossel E, et al. Iron oxide-loaded liposomes for MR imaging. Front Biosci 200813: 4002-8.
102. Hiller KH, Waller C, Nahrendorf M, Bauer WR, Jakob PM. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging 2006; 2(5): 115-21.
103. Doiron AL, Chu K, Ali A, Brannon-Peppas L. Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci USA 2008; 45(105): 17232-7.
104. Sanders HM, Strijkers GJ, Mulder WJ, et al. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media Mol Imaging 2009; 2(4): 81-8.
105. Helm PA, Caravan P, French BA, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagentargeting contrast agent. Radiology 2008; 3(247): 788-96.
106. Chapon C, Franconi F, Lemaire L, et al. High field magnetic resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest Radiol 2003; 3(38): 141-6.
107. Sosnovik DE, Garanger E, Aikawa E, et al. Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Circ Cardiovasc Imaging 2009; 6(2): 460-7.
108. Florian A, Ludwig A, Rosch S, et al. Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction - a cardiovascular magnetic resonance (CMR) study. Int J Cardiol 2014; 2(173): 184-9.
109. Yilmaz A, Dengler MA, van der Kuip H, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur Heart J 2013; 6(34): 462-75.
110. Yilmaz A, Rosch S, Yildiz H, Klumpp S, Sechtem U. First multiparametric cardiovascular magnetic resonance study using ultrasmall superparamagnetic iron oxide nanoparticles in a patient with acute myocardial infarction: New vistas for the clinical application of ultrasmall superparamagnetic iron oxide. Circulation 2012; 15(126): 1932-4.
111. Alam SR, Shah AS, Richards J, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging 2012; 5(5): 559-65.
112. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoEderived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008; 6(3): 233-42.
113. Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosinlabeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992; 2(182): 381-5.
114. Danila D, Johnson E, Kee P. CT imaging of myocardial scars with collagen-targeting gold nanoparticles. Nanomedicine 2013; 7(9): 1067-76.
115. Qureshi A, Gurbuz Y, Niazi JH. Biosensors for cardiac biomarkers detection: A review. Sensor Actuat B-Chem 2012; (171–172): 62-76.
116. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 3(24): 341-56.
117. Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem 200540: 1-36.
118. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001; 13(104): 1483-8.
119. Periyakaruppan A, Gandhiraman RP, Meyyappan M, Koehne JE. Label-free detection of cardiac troponin-I using carbon nanofiber based nanoelectrode arrays. Anal Chem 2013; 8(85): 3858-63.
120. Tang L, Casas J. Quantification of cardiac biomarkers using labelfree and multiplexed gold nanorod bioprobes for myocardial infarction diagnosis. Biosens Bioelectron 201461C: 70-5.
121. Shen W, Tian D, Cui H, Yang D, Bian Z. Nanoparticle-based electrochemiluminescence immunosensor with enhanced sensitivity for cardiac troponin I using N-(aminobutyl)-N-(ethylisoluminol)- functionalized gold nanoparticles as labels. Biosens Bioelectron 2011; 1(27): 18-24.
122. Bhalla V, Carrara S, Sharma P, Nangia Y, Raman Suri C. Gold nanoparticles mediated label-free capacitance detection of cardiac troponin I. Sensor Actuat B-Chem 2012; 1(161): 761-8.
123. Jarvenpaa ML, Kuningas K, Niemi I, et al. Rapid and sensitive cardiac troponin I immunoassay based on fluorescent europium(III)-chelate-dyed nanoparticles. Clin Chim Acta 2012414: 70-5.
124. Yilmaz A, Rosch S, Klingel K, et al. Magnetic resonance imaging (MRI) of inflamed myocardium using iron oxide nanoparticles in patients with acute myocardial infarction - preliminary results. Int J Cardiol 2013; 2(163): 175-82.